Notable 52-Week Highs and Lows of the Day 06/22: (ZAGG) (LLL) (RBN) High; (PHG) (NSPH) (DDSS) Low

This report is an intraday check of some of the more notable stocks that have hit a 52-week high or low so far today.

52-Week High:

• ZAGG Inc. (Nasdaq: ZAGG) high of $15.15. ZAGG investors are going nuts over the iFrogz deal. ZAGG is going to acquire its competitor in a deal valued at $105 million. Shares are up over 20 percent to the new high today.
  
  
• L-3 Communications Holdings Inc. (NYSE: LLL) high of $87.49. LLL is be-boppin' today following an SEC disclosure by activist investor group Relational Investors affirming a 5.98 percent, or 6,347,694 share, stake in the company.
  
  
• Robbins & Myers Inc. (NYSE: RBN) high of $49.34. Robbins & Myers catching a bid today following third-quarter earnings. Earnings in the quarter were 53 cents per share on revs of $237 million, mixed compared with views calling for earnings of 53 cents per share and revs of $211.64 million. Looking ahead, the company boosted its FY11 outlook from $1.95 - $2.15 to $2.23 - $2.33. The consensus is looking for EPS of $2.17. For the fourth-quarter, EPS of 65 to 75 cents per share is expected, versus the consensus of 63 cents.

52-Week Low:

• Koninklijke Philips Electronics NV (NYSE: PHG) low of $22.60. Philips lower after basically cutting its outlook. Philips reports that second-quarter 2011 EBITDA will be adversely impacted due to "weaker than expected market conditions, especially in the consumer sector in Western Europe and construction activity in mature markets." Further, Lighting is expected to report low single-digit comparable sales growth in the second quarter of 2011.
  
  
• Nanosphere, Inc. (Nasdaq: NSPH) low of $1.49. Nanosphere is continuing lower from yesterday, after updating on its premarket approval application following the FDA issuance of a not approvable letter for the Verigene Clopidogrel Metabolism Nucleic Acid Test (Plavix Metabolism). The Company believes the deficiencies cited in the FDA letter are resolvable and ultimately the PMA for the Plavix Metabolism test will be approved by the FDA, although there can be no assurance of such approval. Shares moved an additional 9 percent lower today, after closing 26 percent lower yesterday.
  
  
• Labopharm Inc. (Nasdaq: DDSS) low of $0.1821. Labopharm is to delist from the Nasdaq on June 30, 2011 after the close of business. The company's shares will continue to trade on the Toronto Stock Exchange.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Fisker (FSR) files form 10-K, sees more job cuts, reiterates going concern doubts
• Advent Technologies (ADN) Receives Nasdaq Notice on Late Filing of its Form 10-K
• 10X Capital Venture Acquisition Corp. III (VCXB) Receives NYSE Notice Regarding Late Form 10-K Filing